Phase 2 Trial of Gemcitabine, Cisplatin, plus Ipilimumab in Patients with Metastatic Urothelial Cancer and Impact of DNA Damage Response Gene Mutations on Outcomes

Matthew D. Galsky, Huan Wang, Noah M. Hahn, Przemyslaw Twardowski, Sumanta K. Pal, Costantine Albany, Mark T. Fleming, Alexander Starodub, Ralph J. Hauke, Menggang Yu, Qianqian Zhao, Guru Sonpavde, Michael J. Donovan, Vaibhav G. Patel, John P. Sfakianos, Josep Domingo-Domenech, William K. Oh, Nicholas Akers, Bojan Losic, Sacha GnjaticEric E. Schadt, Rong Chen, Seunghee Kim-Schulze, Nina Bhardwaj, Andrew V. Uzilov

Research output: Contribution to journal › Article › peer-review

Fingerprint

Dive into the research topics of 'Phase 2 Trial of Gemcitabine, Cisplatin, plus Ipilimumab in Patients with Metastatic Urothelial Cancer and Impact of DNA Damage Response Gene Mutations on Outcomes'. Together they form a unique fingerprint.

Medicine & Life Sciences